1-4 of 4
Ruediger Rueger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Free
Michael Andreeff, Kevin R. Kelly, Karen Yee, Sarit Assouline, Roger Strair, Leslie Popplewell, David Bowen, Giovanni Martinelli, Mark W. Drummond, Paresh Vyas, Mark Kirschbaum, Swaminathan Padmanabhan Iyer, Vivian Ruvolo, Graciela M. Nogueras González, Xuelin Huang, Gong Chen, Bradford Graves, Steven Blotner, Peter Bridge, Lori Jukofsky, Steve Middleton, Monica Reckner, Ruediger Rueger, Jianguo Zhi, Gwen Nichols, Kensuke Kojima
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (4): 868–876.
https://doi.org/10.1158/1078-0432.CCR-15-0481
Published: 14 February 2016
View article titled, Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
Open the PDF for Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia in another window
Includes: Supplementary data
Journal Articles

First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors

Free
Maria Martinez-Garcia, Udai Banerji, Joan Albanell, Rastilav Bahleda, Saoirse Dolly, Françoise Kraeber-Bodéré, Federico Rojo, Emilie Routier, Ernesto Guarin, Zhi-Xin Xu, Ruediger Rueger, Jean J. L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jean-Charles Soria
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4806–4819.
https://doi.org/10.1158/1078-0432.CCR-12-0742
Published: 30 August 2012
View article titled, First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
Open the PDF for First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors

Free
Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber-Bodéré, Veronique Dieras, Max E. Scheulen, Avinash Gupta, Vanesa Lopez-Valverde, Zhi-Xin Xu, Ruediger Rueger, Jean J.L. Tessier, Eliezer Shochat, Steve Blotner, Valerie Meresse Naegelen, Jan H.M. Schellens, Wilfried Ernst Erich Eberhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (17): 4794–4805.
https://doi.org/10.1158/1078-0432.CCR-12-0868
Published: 30 August 2012
View article titled, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker

Free
Lucy Lee, Huifeng Niu, Ruediger Rueger, Yuriko Igawa, Jonathan Deutsch, Nobuya Ishii, Song Mu, Yuuichiro Sakamoto, Rachel Busse-Reid, Claude Gimmi, Petra Goelzer, Stefanie De Schepper, Yashushi Yoshimura, Joanne Barrett, Yuji Ishikawa, Georges Weissgerber, Richard Peck
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7368–7374.
https://doi.org/10.1158/1078-0432.CCR-09-1696
Published: 30 November 2009
View article titled, The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
Open the PDF for The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker in another window